Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501-Update on maintenance treatment, progression-free survival (PFS), and overall survival (OS).

被引：4

作者：

Aisner, J.

Manola, J.

Dakhil, S. R.

Stella, P. J.

Schiller, J. H.

机构：

[1] Canc Inst New Jersey, New Brunswick, NJ USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Wichita Community Clin Oncol Program, Wichita, KS USA

[4] St Joseph Mercy Hlth Syst, Ann Arbor, MI USA

[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

来源：

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.7560

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7560

引用

页数：1